Related Blog Posts from the Wikinvest Wire

Amarin (AMRN)   Subscribe to Amarin (AMRN) content from the Wikinvest Wire
 » Back to Amarin (NASDAQ:AMRN) Stock Page

  

6/15/13Amarin Corporation plc Trading targets (Trading with the Average Jay)

Here are my possible Entry/Exit targets for Amarin Corp (AMRN) for the upcoming week. Please remember that any information presented on this blog is for entertainment only. Use of any trading ideas presented on my site is at your own risk. Everyone have a great week of trading. I would appreciate any comments about this post (positive or negative.) Update 6/18 08:30 . Using my chart buy trade opened at 6.60. Profit target 6.84 in front of prior supply zone. Update 6/23 20:42. ...

6/10/13Amarin Corporation plc (Trading with the Average Jay)

This mornings trade was a short entry with Amarin Corporation plc (AMRN.) The market was down with declining stocks in the -700-600 range on the $ADD chart. I used the 50% line of the 30 min open chart red candle as an entry point. The market started to turn up so I took myself out of the trade for a VERY small profit. I call this a winning trade. I acted to what was going on in front of me instead of waiting the trade to play out and hit a stop for a loss. I used the "just like playing cards...

1/23/13(AMRN) Amarin Corporation Aims to Fortify Vascepa Patent (Stock Blog Hub)

Amarin Corporation plc (AMRN), recently announced that the notice of patent allowance for US application serial number 13/610,217 has been published by the US Patent and Trademark Office (USPTO). The patent application aims to protect Vascepa (icosapent ethyl) till 2030. We note that in Jul 2012, the US Food and Drug Administration (FDA) approved Vascepa as [...]

4/16/12Baupost Group Drops Targacept While SAC Buys Amarin (ValueWalk.com)

  Several major investors made moves in the pharmaceuticals arena last week as the ups and downs in that industry came to the fore. The Baupost Group sold off its entire holdings of the Biotechnology firm Targacept Inc. (NASDAQ:TRGT) and SAC Capital advisers continued to increase its stake in the pharmaceuticals research firm Amarin Corporation plc (NYSE:AMRN). [...]

4/16/12SAC Capital Buys More Amarin (AMRN) (market folly)

Steve Cohen 's hedge fund SAC Capital filed a 13G with the SEC regarding its position in Amarin (AMRN). Per the filing, the firm now owns 5.3% of the company with 7,216,209 shares. This marks a 33% increase in their position size since the last disclosure. This is the second subsequent purchase of AMRN shares by the hedge fund in the past month or so. The latest disclosure was made due to trading activity on April 3rd. Per Google Finance, Amarin is "a clinical-stage biopharmaceutical...

3/26/12SAC Capital Starts Hyatt Hotels Position, Boosts Amarin Stake (market folly)

Steve Cohen 's hedge fund firm SAC Capital just filed two separate 13G's with the SEC: Hyatt Hotels (H) First, the hedge fund disclosed it has initiated a brand new position in Hyatt Hotels (H) with 2,804,400 shares, which is a 6.2% ownership stake in the company. They did not own any shares at the end of 2011. They filed the disclosure today due to portfolio activity on March 14th when they crossed the regulatory threshold. This is the second hotel/hospitality-related transaction...

11/26/11InterOil, Green Dot, Amarin are big market movers (Penny Stock DD)

Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and Nasdaq Stock Market: NYSE InterOil Corp., up $3.26 at $55.64 The oil and gas company and Pacific LNG signed a deal with Gunvor Singapore to supply liquefied natural gas from Papua New Guinea. Green Dot Corp., up 57 cents at $30.19 The California-based prepaid [...]

11/22/11Biotech: Amarin (AMRN) – Summary & Analysis Of Patents & Patent Applications (IP) – Part 1 ()

I weighed in on Amarin $AMRN and its triglyceride lowering drug AMR101 in a recent blog post about the chances of the FDA granting new chemical entity (NCE) status. Another hot topic of discussion and a recent reason for a drop in the value of AMRN shares is concerns over intellectual property protection for the drug (or [...]

11/19/11Biotech: Amarin (AMRN) Notes From Lazard Webcast 11/15/2011 ()

I have just recently started to assemble coverage of Amarin on BiotechDueDiligence (and recently bought my first shares) - here is the link to the AMRN research page under construction. Visit the Upcoming Events and Past Events pages for schedules, links, and my notes for all the companies I cover. My notes from the webcast are below: SPA's took 3-9 months additional time to [...]

11/12/11Biotech: Useful Document RE: Amarin NCE Status ()

Just a quick note.  The narrative in this Citizen's Petition rejection related to Vitrase (ovine hyaluronidase) from ISTA Pharmaceuticals is also helpful in assessing the chances that Amarin $AMRN will receive New Chemical Entity (NCE) status from the FDA for its triglycerides lowering product. Previously, I posted an extensive review of the subject here on the Biotech Due Diligence blog. Related: CLICK HERE FOR [...]

11/4/11Will Patent Protection Derail Amarin's Miracle Fish Pill? (Benzinga)

Shares in Amarin Corporation recently fell 10%, due to a decision by the US Patent and Trademark Office to issue a non-final rejection of a patent linked to AMR101, a lipid reduction drug that helps to treat high levels of triglycerides in patients. The company had previously announced that the drug was highly effective in reducing levels of triglycerides in a pair of Phase 3 trials, and is considered to have blockbuster potential, with some analysts projecting sales up to $2 billion a year,...

7/18/11Amarin Corp Climbs On Takeover Speculation (Stock Wizard)

Shares of Amarin Corp. plc (NASDAQ: AMRN) rose as much as 2% on Monday on speculation that the company could be acquired by Pfizer Inc. (NYSE: PFE). Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. Its lead product candidate includes AMR101, a prescription grade omega-3 fatty acid, which is in second Phase III clinical trial for the treatment of high triglyceride levels in statin-treated patients who have mixed...

5/19/11AMRN, PETM, SODA, TWER Among Charts to Watch (Wall Street Sector Selector)

There are still quite a few stocks that look good on our board so we are going to continue looking at the ones that stand out the most. Amarin Corporation plc (AMRN), which has been consolidating very nicely after the big pop up last month, ...

4/19/11(AMRN) Company News for April 19, 2011 – Corporate Summary (Stock Blog Hub)

• Amarin's (NASDAQ:AMRN) share prices sky rocketed 95% after promising results from a new cholesterol drug led to speculation that the company could soon be a takeover target for Big Pharma • Share prices of Marvell (NASDAQ:MRVL) dropped 4.57% after Susquehanna downgraded the stock to "Neutral" from "Positive" and slashed the target price to $17 from $23 • Late on [...]

4/19/11AMRN, COOL, MOBI, YOKU Among Charts to Watch (Wall Street Sector Selector)

There are still a lot of good looking charts on the long side. The market has been struggling, but we’ve managed to call out some of the top stocks. Amarin Corporation plc (AMRN), which we’ve been watching for weeks, broke out of...

4/18/11Hot Stocks Of The Day: AMRN, INVE, MRVL, AONE, THC (Stock Wizard)

Below we highlight few companies whose shares are actively trading in Monday's session. Amarin Corporation plc (NASDAQ: AMRN) soared more than 70% after the company reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses. The purpose of the ANCHOR trial was to demonstrate that AMR101 is effective in...

1/11/11Bullish Pharmaceutical Stocks at NASDAQ : (MNKD, AMRN, BPAX, LXRX, THOR) (Penny Stock DD)

MannKind Corporation (NASDAQ:MNKD) went up by 2.44% and closed at $8.40 whereas overall traded volume stood at 2.05 million shares for the day. The company maintains strong short term liquidity position with current ratio of 3.99 times. The current market price is 20.43% more than its last 50 days simple moving average. Amarin Corporation plc [...]

1/7/11High Momentum Pharmaceutical Stocks at NASDAQ: (LXRX, DSCOD, AMRN, HLCS, NMTI) (Penny Stock DD)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) jumped up by 45.70% to close at $2.20 with overall traded volume of 20.61 million shares in the last trading day. The RSI value of 78.02 times depicts that the current share value is in highly overbought level. The company maintains strong short term liquidity position with current ratio of 18.20 [...]

11/29/10Trading results 11/29/10 (Robert Weinstein Trading Blog)

Once again a slow Monday. I did have a few trades but nothing that really ran hard. I did a lot of shares with AMRN and faded the gap higher. This would be a good example of how being with a cheaper broker would really matter. I had plenty of buying power left [...]

11/29/10Stocks Resilient After Morning Slide (ZQK, WMT, BP, AMRN) (tickerspy.com)

Despite encouraging signs that the holiday shopping season is off to a good start, stocks finished lower as European debt woes and a strengthened dollar weighed down the market. Nonetheless, the solid Black Friday weekend shopping data has to be viewed as encouraging, as consumers scooped up both gifts and goods for themselves. While the [...]

8/30/10DRD Pick for tomorrow ARMN (Penny Stock DD)

[wikichart align="right" ticker="NASDAQ:AMRN" showannotations="true" livequote="true" startdate="02-03-2010" enddate="30-08-2010" width="300" height="245"] Amarin Corporation Plc (AMRN) 3.12    +0.16 (+5.41%)   Monday, Aug 30th, 2010 Profile  Company Information Ticker Symbol: AMRN Exchange: NASDAQ Contact Info: CEO / President: Industry/Sector: Top 100 Stocks, Medical - Biomedical SIC Code: SIC-2834 Pharmaceutical...


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki